From CARs to CHARs and CAARs

Description

Differences between a chimeric antigen receptor (CAR) and ligand-based CAR, such as CHARs or CAARs, lie in their recognition mechanism. While a CAR uses a single-chain variable fragment (ScFv) to recognize antigens, CHARs or CAARs have the antigen itself as an extracellular domain, which is recognized by a B cell receptor (BCR). CAARs or CHARs are emerging as targeted therapies for autoimmune diseases and the management of humoral rejection in kidney transplants.

Acknowledgements

References

Ramírez-Chacón A, Betriu-Méndez S, Bartoló-Ibars A, González A, Martí M and Juan M (2022) Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments. Front. Immunol. 13:932559. doi: 10.3389/fimmu.2022.932559 Velasco-de Andrés, M., Muñoz-Sánchez, G., Carrillo-Serradell, L., Gutiérrez-Hernández, M.d.M., Català, C., Isamat, M. and Lozano, F. (2023), Chimeric antigen receptor–based therapies beyond cancer. Eur. J. Immunol., 53: 2250184. https://doi.org/10.1002/eji.202250184

Get started with this template for free

Don’t start from scratch.

Create professional scientific illustrations quickly and easily, even without any design expertise

Get started with a huge library of editable icons and templates such as common biological pathways, anatomy, or genetics.
Create figures that effectively communicate your research in half the time using our editable icons.
Use our PDB tool to quickly generate and customize protein structures

Get started now